MARKET

AMPH

AMPH

Amphastar Pharma
NASDAQ
53.41
+1.50
+2.89%
After Hours: 53.41 0 0.00% 16:02 02/23 EST
OPEN
52.30
PREV CLOSE
51.91
HIGH
53.55
LOW
51.91
VOLUME
289.06K
TURNOVER
0
52 WEEK HIGH
67.66
52 WEEK LOW
31.81
MARKET CAP
2.56B
P/E (TTM)
20.85
1D
5D
1M
3M
1Y
5Y
Amphastar Pharmaceuticals Insiders Sold US$2.6m Of Shares Suggesting Hesitancy
Amphastar Pharmaceuticals, Inc. Insiders sold US$730k worth of shares in the last year. The biggest insider sale was by Michael Zasloff for US$57.22 per share. Amphastar pharmaceuticals insiders didn't buy any shares over the last 12 months. The company has a 7.2% of the company, currently worth about US$180m. It's important to look at the recent insider transactions of Amphastor Pharmaceuticals.
Simply Wall St · 3d ago
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
NASDAQ · 4d ago
Weekly Report: what happened at AMPH last week (0212-0216)?
Weekly Report · 6d ago
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
NASDAQ · 02/14 11:20
3 Pharma Stocks to Buy for February Gains
Amphastar Pharmaceuticals, Inc. (AMPH), Bausch Health Companies (BHC), and ACADIA Pharmaceuticals (ACAD) are fundamentally strong pharma stocks. The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs. The industry's growth prospects look promising due to rise in chronic diseases, a rapidly aging population, and the development of drugs for rare conditions. Amphastar pharmaceuticals,  could be wise to consider buying these three companies.
Barchart · 02/13 13:35
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
NASDAQ · 02/13 11:20
Weekly Report: what happened at AMPH last week (0205-0209)?
Weekly Report · 02/12 09:09
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
NASDAQ · 02/09 22:45
More
About AMPH
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. It operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Its portfolio also includes BAQSIMI (BAK-see-mee), which is used to treat very low blood sugar in people with diabetes ages 4 years and above.

Webull offers Amphastar Pharmaceuticals Inc stock information, including NASDAQ: AMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMPH stock methods without spending real money on the virtual paper trading platform.